TMC Life Sciences Berhad (KLSE:TMCLIFE)

Market Cap	705.46M
Revenue (ttm)	326.39M
Net Income (ttm)	2.21M
Shares Out	1.74B
EPS (ttm)	0.00
PE Ratio	319.65
Forward PE	n/a
Dividend	0.02 (5.47%)
Ex-Dividend Date	Dec 5, 2024

Volume	35,500
Average Volume	106,425
Open	0.4000
Previous Close	0.4050
Day's Range	0.4000 - 0.4050
52-Week Range	0.3650 - 0.6200
Beta	0.41
RSI	42.78
Earnings Date	Aug 22, 2025

About Orchard Therapeutics

TMC Life Sciences Berhad, an investment holding company, provides healthcare services in Malaysia. The company operates Thomson Hospital Kota Damansara (THKD), a medical bedded center located in Selangor. Its THKD provides women and children health, cancer, orthopedics, ENT, head and neck laser, gastro, hepato, urology, fertility health services. In addition, the company’s reproductive treatment comprises in-vitro fertilisation, preimplantation genetic testing, fertility preservation, laparoscopic surgery, surgical sperm retrieval, and donation...

• Industry: Miscellaneous Health And Allied Services, Not Elsewhere Classified
• Founded: 1994
• Country: Malaysia
• Stock Exchange: Bursa Malaysia
• Ticker Symbol: TMCLIFE

Financial Performance

In 2024, TMC Life Sciences Berhad's revenue was 346.42 million, an increase of 11.19% compared to the previous year's 311.56 million. Earnings were 40.65 million, an increase of 3.54%.